| Geneva Homologous Recombination Deficiency Test Is Predictive of Survival Benefit From Olaparib and Bevacizumab Maintenance in Ovarian Cancer | JCO precision oncology |  | | 2025 | 23 | 73 |
|
| Reporting of somatic variants in clinical cancer care : recommendations of the Swiss Society of Molecular Pathology | Virchows Archiv | | | 2024 | 59 | 130 |
|
| BRCA2 germline mutation carrier with five malignancies : a case report | Hereditary Cancer in Clinical Practice | | | 2024 | 36 | 269 |
|
| High concordance of different assays in the determination of homologous recombination deficiency-associated genomic instability in ovarian cancer | JCO precision oncology | | | 2024 | 117 | 154 |
|
| Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma | JCO precision oncology | | | 2023 | 115 | 153 |
|
| Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab | Gynecologic Oncology Reports | | | 2021 | 268 | 154 |
|
| Automated Detection of Arm-Level Alterations for Individual Cancer Patients in the Clinical Setting | The journal of molecular diagnostics | | | 2021 | 207 | 359 |
|
| Tissue-plasma TMB comparison and plasma TMB monitoring in patients with metastatic non-small cell lung cancer receiving immune checkpoint inhibitors | Frontiers in Oncology | | | 2020 | 300 | 317 |
|
| Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss | Cancer Biology and Therapy | | | 2020 | 359 | 221 |
|
| Targeted RNA-sequencing identifies FBXW4 instead of MGEA5 as fusion partner of TGFBR3 in pleomorphic hyalinizing angiectatic tumor | Virchows Archiv |  | | 2019 | 400 | 0 |
|
| Towards optimal pancreatic cyst fluid management: the need for standardisation | Gut | | | 2018 | 381 | 0 |
|
